🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
UroGen Pharma Ltd. (URGN)
NASDAQ: URGN · Real-Time Price · USD
32.10
+2.31 (7.75%)
Nov 19, 2026, 1:58 PM EST - Market open

UroGen Pharma Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
250.25109.7990.482.7164.3648.04
Revenue Growth
159.29%21.45%9.29%28.52%33.96%307.17%
Cost of Revenue
21.512.458.889.367.655.16
Gross Profit
228.7597.3481.5273.3556.742.89
Selling, General & Admin
186.48155.1120.0593.2782.8487.54
Research & Development
73.2167.1157.1545.6152.9147.64
Operating Expenses
259.69222.2177.2138.89135.74135.18
Operating Income
-30.94-124.86-95.68-65.54-79.04-92.29
Interest Expense
-17.68-15.35-12.52-14.72-8.44-
Interest & Investment Income
3.475.978.92.640.940.37
Other Non Operating Income (Expenses)
-19-19.17-23.64-20.71-21.49-17.44
EBT Excluding Unusual Items
-64.15-153.42-122.94-98.32-108.03-109.37
Other Unusual Items
---1.1---
Pretax Income
-64.15-153.42-124.04-98.32-108.03-109.37
Income Tax Expense
1.60.082.833.921.761.45
Net Income
-65.75-153.49-126.87-102.24-109.78-110.82
Net Income to Common
-65.75-153.49-126.87-102.24-109.78-110.82
Net Income Growth
------
Shares Outstanding (Basic)
504843292322
Shares Outstanding (Diluted)
504843292322
Shares Change
5.29%12.22%48.70%26.43%2.05%2.60%
EPS (Basic)
-1.31-3.19-2.96-3.55-4.81-4.96
EPS (Diluted)
-1.31-3.19-2.96-3.55-4.81-4.96
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-132.05-162.73-97.06-76.57-87.81-85.64
Free Cash Flow Per Share
-2.64-3.38-2.26-2.66-3.85-3.83
Gross Margin
91.41%88.66%90.18%88.68%88.11%89.27%
Operating Margin
-12.36%-113.73%-105.84%-79.23%-122.82%-192.11%
Profit Margin
-26.27%-139.81%-140.35%-123.61%-170.58%-230.67%
Free Cash Flow Margin
-52.77%-148.22%-107.37%-92.57%-136.45%-178.27%
EBITDA
-30.63-124.56-95.35-64.73-78.12-91.46
EBITDA Margin
-12.24%-113.45%-105.48%-78.26%-121.38%-190.38%
D&A For EBITDA
0.310.310.330.80.920.83
EBIT
-30.94-124.86-95.68-65.54-79.04-92.29
EBIT Margin
-12.36%-113.73%-105.84%-79.23%-122.82%-192.11%
SEC Filings: 10-K · 10-Q